BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dynavax Technologies Corporation (DVAX) Falls After Vaccine Fails to Win Panel Backing


11/16/2012 7:18:36 AM

Dynavax Technologies Corp. (DVAX) tumbled as much as 60 percent in early trading after its hepatitis B vaccine failed to win the backing of U.S. regulatory advisers as the drugmaker seeks to bring its first product to market. Dynavax fell 57 percent to $1.98 at 7:36 a.m. New York time, after dropping to $1.87. While Heplisav works to treat the contagious liver disease, Dynavax didn’t provide adequate safety data to support approval, Food and Drug Administration advisers voted yesterday. The FDA, set to make a decision by Feb. 24, isn’t required to follow the panel’s guidance. Dynavax, based in Berkeley, California, billed the drug as a way to protect healthy adults 18 to 70 years old. Panel members that called Heplisav promising cited the small number of patients Dynavax studied given the vaccine’s potential to cause rare autoimmune diseases. “Since we have vaccines that maybe aren’t as optimal as we want but are effective, that is too flimsy,” Edgar Marcuse, a panel member and associate medical director at Seattle Children’s Hospital, said during the meeting in Silver Spring, Maryland.


 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES